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Abstract
Objectives—The Malawi antiretroviral therapy (ART) programme uses the public health 
approach to identify ART failure. Advanced disease progression may occur before switching to 
second-line ART. We report outcomes for patients evaluated and initiated on second-line treatment 
in Malawi.
Methods—Patients meeting Malawi immunological or clinical criteria for ART failure in two 
large urban ART clinics were evaluated for virological failure (viral load >400 HIV-1 RNA 
copies/mL) and, if failure was confirmed, initiated on second-line ART (zidovudine/lamivudine/
tenofovir/lopinavir/ritonavir). Patients were seen monthly and laboratory evaluations were 
performed quarterly and as needed. We performed logistic regression modelling to identify factors 
associated with mortality, mortality or new HIV illnesses, and virological suppression at 12 
months.
Results—Of the 109 patients with confirmed virological failure, five patients died prior to 
initiation, three declined switching and 101 patients initiated second-line treatment. Over 12 
months, 10 additional patients died, 34 patients experienced 45 HIV-related events, and 19 patients 
experienced grade 3 or 4 toxicities. Among survivors, 85.2% had HIV-1 RNA<400 copies/mL at 
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12 months. While power to distinguish differences was limited, response rates were similar 
regardless of baseline resistance level. The median CD4 count increase was 142 cells/μL. World 
Health Organization clinical failure at baseline [odds ratio (OR) 3.47; 95% confidence interval 
(CI) 1.14–10.59] and body mass index <18.5 (OR 4.43; 95% CI 1.15–17.12) were risk factors for 
death. Baseline CD4 count <50 cells/μL was associated with increased risk for death or morbidity 
at 12 months (OR 2.57; 95% CI 1.01–6.52).
Conclusions—Second-line treatment in Malawi was associated with substantial mortality, 
morbidity and toxicity but, among survivors, virological outcomes were favourable.
Keywords
antiretroviral therapy; HIV resistance; Malawi; resource-limited setting; mortality; second line
Introduction
The Malawi national antiretroviral therapy (ART) programme is implemented using the 
public health approach [1]. Patients start ART based mainly on World Health Organization 
(WHO) clinical staging, and the Malawi guidelines recommend switching therapy for failure 
determined by immunological or clinical criteria [2]. HIV-1 RNA monitoring is not a part of 
the ART programme. Since the free ART programme began in 2004, over 220 000 
Malawians have been started on the standard first-line ART regimen, a fixed-dose 
combination of nevirapine (NVP), stavudine (d4T) and lamivudine (3TC) [3]. With the large 
population on treatment, regimen failure is inevitable in a substantial number of patients. 
Currently, the Malawi ART programme recommends a combination of zidovudine (ZDV), 
3TC, tenofovir (TDF) and lopinavir/ritonavir (LPV/r) for those failing the first-line regimen 
[2,4]. The rationale of the three-nucleoside reverse transcriptase inhibitor (NRTI) backbone 
is to provide empirical coverage of accumulated mutations, given that failure will often be 
identified late as a result of the clinical and immunological monitoring strategy, on the 
assumption that 3TC may have residual activity, and that maintaining the M184 mutation 
increases the susceptibility of HIV to ZDV or TDF [5–8].
In Malawi, high levels of NRTI resistance are present when ART failure is detected using 
clinical and immunological criteria [9]. Approximately 17% of patients would be expected 
to have no fully active NRTI agents, even with the three-NRTI backbone. Similar paucity of 
active NRTI agents for second-line treatment has been noted in Thailand [10]. While LPV/r 
has been used successfully as monotherapy in ART-naïve populations [11,12], how failing 
patients will respond to an LPV/r-based second-line regimen with a suboptimal NRTI 
backbone has not been extensively studied.
To date, there are few data on the response to second-line treatment in resource-limited 
settings, particularly in the setting of confirmed extensive drug resistance. We aimed to 
document the response to second-line ART among Malawian patients with confirmed 
virological failure after identification by clinical and immunological means.
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This prospective cohort study was conducted at two urban sites in Lilongwe and Blantyre, 
Malawi, both following approximately 4000 patients on ART during the study period 
(January 2006 to July 2008). These were the only government clinics in Malawi with access 
to free second-line ART. Laboratory tests were performed at the University of North 
Carolina Research Project, Lilongwe and at the College of Medicine-Johns Hopkins 
Research Project, Blantyre.
Population and design
Patients older than 13 years suspected of failing a standard first-line ART regimen consisting 
of NVP, or efavirenz in the case of previous NVP toxicity, 3TC and d4T, or ZDV in the case 
of previous d4T toxicity, were referred to the study teams. Patients were reviewed to confirm 
immunological failure (based on documented CD4 trends) and/or clinical failure (new or 
progressive WHO stage IV conditions). Patients with viral load >400 HIV-1 RNA copies/mL 
were defined as virological failures and those with low-level viraemia (400–1000 
copies/mL) were confirmed prior to switching to second-line treatment. First-line therapy 
was maintained until the switch to second-line therapy occurred. All patients initiating 
second-line treatment within the public sector of the national ART programme at these 
centres during January 2006 to July 2007 were included in this study.
Follow-up procedures
Patients were assessed monthly for toxicity, new WHO clinical stage 2, 3 or 4 events, and 
adherence through a short questionnaire and pill counts. HIV-1 RNA measurements (Roche 
Amplicor®; Roche, Basel, Switzerland; detection level 400 copies/mL), Complete Blood 
Count (CBC), CD4 cell counts [either FacsCount (Becton-Dickinson, Franklin Lakes, NJ, 
USA) or EPICS-MCL Pan-Leuco Gating method (Beckman Coulter, Brea, CA, USA)], liver 
function tests, and serum creatinine and random blood glucose measurements were 
performed at baseline and every 3 months or as clinically indicated. Genotype testing 
(TruGene HIV-1 Genotyping Kit; Siemens Medical Solutions Diagnostics, Tarrytown, NY, 
USA) on baseline samples was retrospectively performed for all patients with HIV-1 
RNA>1000 copies/mL and was not available for clinical decision-making [9].
We managed TDF renal toxicity by substitution with abacavir (ABC), depending on 
availability; otherwise TDF was just discontinued. Patients with anaemia or neutropenia 
secondary to ZDV received either TDF/d4T/3TC or TDF/3TC. No substitute for LPV/r was 
available.
In the event of tuberculosis (TB) at failure identification, patients in Blantyre were 
maintained on first-line treatment until completion of TB treatment. In the case of incident 
TB during second-line treatment, ART was stopped. In Lilongwe, rifabutin was available 
and patients received rifabutin-based TB treatment concurrently with LPV/r-based ART.
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The study was approved by the Malawi National Health Sciences Research Committee and 
the University of North Carolina School of Medicine Committee for the protection of human 
subjects. Written informed consent was obtained from all patients.
Outcome measurements
Outcomes included mortality, loss to follow-up (no visits within 90 days prior to or 30 days 
after the 12-month time-point) and any new WHO stage 2, 3 and 4 clinical events collected 
at each visit [1]. Laboratory evaluations were graded according to the division of AIDS 
(DAIDS) toxicity tables [13]. Creatinine clearance was calculated using the Cockcroft–Gault 
equation. We recorded any toxicity that led to treatment change, regardless of grade. The 
proportion of patients achieving HIV-1 RNA<400 copies/mL and the CD4 cell count was 
measured at 3, 6, 9 and 12 months. Cause of death was determined by chart review.
We evaluated adherence using the number of missed visits and the proportion of visits with 
no missed doses, and compared ‘never missed’ doses vs. ‘ever missed’ over the 12-month 
time period.
For resistance analysis, we categorized mutations according to the International AIDS 
Society USA (IAS-USA) recommendations [14] and categorized patients according to the 
number of active NRTI drugs based on the baseline genotype pattern. Those with only 
M184V and NNRTI mutations or wild-type virus were considered to have at least two fully 
active NRTI drugs or ‘low’ resistance; patients with any thymidine analog mutations 
(TAMs) or K65R/70E or Q151M were considered to have at least one fully active NRTI 
drug or ‘medium’ resistance; and patients with the 69 insertion or Q151M complex in 
combination with K65R or K70E were considered to have no active NRTI drugs or ‘high’ 
resistance. Additionally, we evaluated responses in patients with wild-type virus, any TAMs, 
and at least three TAMs.
Statistical considerations
In all analyses, STATA v.10 (STATA Corp., College Station, TX, USA) was used. Student’s 
t-test and the χ2 or Fisher’s exact test were used to compare continuous and categorical 
variables, respectively.
We performed logistic regression analysis to identify factors associated with mortality, 
mortality and/or morbidity (new WHO stage 3 or 4 clinical event) at 6 and 12 months, and 
virological suppression to HIV-1 RNA<400 copies at 12 months. For the mortality, and 
mortality and/or morbidity models, all confirmed first-line ART virological failures were 
included; however, for the virological suppression model, only those initiating second-line 
treatment were included. For all models, factors considered included age, gender, means of 
failure identification (any clinical vs. immunological only), HIV-1 RNA and CD4 cell count 
at time of failure identification, duration of first-line ART before presentation, haemoglobin 
and body mass index (BMI). Additionally, adherence measures (self report of ever having 
missed a dose/not having missed a dose) and degree of baseline resistance were included as 
factors in the model related to virological suppression. Categories for continuous variables 
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(age, CD4 cell count, HIV-1 RNA, duration on ART, BMI and haemoglobin) were chosen 
for clinical significance and to be consistent with the previous literature.
For the HIV suppression model, we employed intent-to-treat analysis with deaths and loss to 
follow-up, but not treatment switches because of toxicity, considered as failures. Model 
diagnostics were performed and, in the event of significant collinearity between variables, 
only one was included in the final multivariate model.
Results
Among the approximately 8000 ART patients currently in follow-up and 54 external 
referrals, we evaluated 203 patients for suspicion of treatment failure based on clinical and 
immunological criteria (Fig. 1). Of these, 109 patients were recommended for switch to 
second-line ART after confirmation of virological failure. Five patients died prior to second-
line ART initiation (Figs 1 and 2) with a median time between screening and death of 19 
days (range 7–24 days). Three patients declined switching in the government clinics and 
were excluded from follow-up analysis.
Patients initiating second-line treatment (n = 101) had a median [interquartile range (IQR)] 
CD4 count of 65 (22–173) cells/μL and HIV-1 RNA of 52 939 (15 739–148149) copies/mL 
(Table 1). As previously described [9], the population had extensive baseline resistance 
mutations to the NRTI class of drugs (Table 1), but no patient had any mutations associated 
with LPV/r resistance.
Clinical outcomes and clinical progression
Among 101 patients who initiated second-line treatment, 10 patients (10%) died during the 
12 months of follow-up (Fig. 2). All deaths occurred in the first 6 months of treatment, with 
six deaths in the first 3 months post initiation.
Primary causes of death among patients with confirmed virological failure (n = 106) 
included: Kaposi sarcoma (KS) (four patients), TB (two), sepsis (two), wasting syndrome 
(one), anaemia (one) and other (five). Three patients were lost to follow-up between 6 and 
12 months. HIV-related illnesses were common during the follow-up period. Thirty-four 
patients experienced 45 HIV-related events during the 12 months after the initiation of 
second-line treatment, and 69% of events occurred in the first 6 months. Events included 
bacterial pneumonia [13], KS progression [11], TB (seven), oral candidiasis (nine), sepsis 
(two) and progressive cryptococcal meningitis (three).
Overall, 15 patients required TB treatment either at initiation (eight patients) or during 
second-line treatment (seven patients). Eight patients completed rifabutin-based treatment, 
and one died before initiating the rifabutin-based treatment. Six received rifampicin-based 
treatment before initiation of second-line ART, of whom one died prior to commencing 
second-line ART.
On multivariate analysis, clinical failure as the indicator of first-line failure and BMI<18.5 
were independent risk factors of death at 12 months among all virologically confirmed 
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patients (n = 106) (Table 2). At both 6 and 12 months, CD4<50 cells/μL was independently 
associated with death and morbidity (Table 2).
Toxicity
Twenty-eight grade 3 or 4 toxicities occurred in 19 individuals after second-line ART 
initiation. These included haemoglobin <7.5 mg/dL (nine cases), absolute neutrophil count 
<750 cells/μL (11), creatinine >2.3 mg/dL (three), creatinine clearance <50 mL/min (15), 
glucose >251 mg/dL (three), and lactate >3.5 mmol/L (two). ZDV was discontinued because 
of either anaemia or neutropenia in seven patients. In four subjects with renal toxicity, TDF 
was substituted with ABC, and in one case of lactic acidosis all NRTIs including TDF were 
discontinued. LPV/r was not discontinued because of toxicity in any patient.
Adherence
Among patients initiating treatment, 55% reported never missing a dose throughout the 
study period. Likewise, 55% of patients never missed a clinic visit but 29% of patients 
missed one visit, 11% missed two visits, and 5% missed three visits.
Immunological and virological outcomes
Among survivors, the median increase in CD4 count was 142 cells/μL (IQR 66, 263) at 12 
months and 85% of these patients had HIV-1 RNA<400 copies/mL at 12 months (Fig. 3). 
Overall, 75% of the 101 patients who started second-line therapy survived and were 
suppressed (Fig. 3). Of the 13 patients who had HIV-1 RNA>400 copies/mL at month 12, 
six were never suppressed and seven had initial suppression but rebounded.
On treatment, the HIV-1 RNA suppression rate for patients with wild-type virus was 60% 
[95% confidence interval (CI) 15–95%] compared with 94% (95% CI 87–100%) for patients 
with any TAMs and 95% (95% CI 85–100%) for those with at least three TAMs. HIV-1 
RNA suppression rates varied according to the number of active NRTI drugs: at least two 
active drugs (low), 71% (95% CI 50–93%); one active drug (medium), 92% (95% CI 85–
100%); and no active drugs (high), 97% (95% CI 77–100%). Adherence rates (never missed 
doses) were 48% for those with at least two active drugs (low), 59% for those with one 
active drug (medium), and 56% for those with no active drugs (high) (P = 0.7), which 
corresponded to HIV-1 RNA suppression rates of 90% for those with at least two active 
drugs (low), 96% for those with one active drug (medium), and 89% for those with no active 
drugs (high) (P = 0.6). Among patients who ever missed doses, HIV-1 RNA suppression 
rates were 55% for those with at least two active drugs (low), 84% for those with one active 
drug (medium), and 85% for those with no active drugs (high) (P = 0.15).
Factors associated with HIV-1 RNA>400 copies/mL at 12 months on univariate analysis 
included having a presenting CD4 count <50 cells/μL and HIV-1 RNA > 100 000 copies/mL 
(Table 3). Paradoxically, having extensive baseline resistance resulted in better virological 
suppression (Table 3). However, on multivariate analysis, only poor adherence (ever missing 
a dose) remained statistically significant. Duration on first-line treatment >3 years was not 
associated with increased risk of failure.
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In our cohort of ART failure patients identified by clinical and immunological criteria in the 
public health setting who were confirmed to have virological failure, there is substantial 
early mortality on second-line ART. Identification of failure by clinical criteria, in particular, 
was associated with an increased risk of death in the first 6 months as well as new and 
progressive HIV-associated illnesses. However, among survivors, high rates of virological 
suppression and good immunological recovery occurred despite extensive baseline 
resistance. As with most ART studies, we found adherence to be a significant factor in the 
successful suppression of HIV-1 RNA.
Early mortality upon initiation of first-line ART has been well described in resource-limited 
settings [15–18] and predictors for mortality have consistently included low BMI, low CD4 
cell count and anaemia [15–19]. Low BMI and low CD4 cell counts were similarly 
associated with early HIV-associated illnesses and mortality in our cohort of patients 
initiating second-line ART and in a study of second-line ART patients treated in Médecins 
Sans Frontières (MSF) programmes [20]. Additionally, the mortality prior to initiation of 
second-line ART mirrors mortality before initiation of first-line treatment [21–23]. The 
striking similarity of severe events occurring around initiation of first- and second-line ART 
in resource-limited settings suggests that the advanced stage of HIV disease of patients in 
both situations is the underlying cause. The primary reason why our ART failure patients 
were in such advanced stages of disease is likely to be the reliance on clinical and, less 
consistently, immunological monitoring for identification of ART failure in the Malawi ART 
programme. The results from our second-line programme may improve over time if 
clinicians become more experienced in identifying ART failure, and if second-line ART 
becomes more widely available outside tertiary centres, avoiding lengthy referral 
procedures.
We have previously demonstrated a complex array of mutation patterns in this patient cohort 
such that 17% of patients would be expected to have no active NRTI in the second-line 
regimen and an additional 68% would have reduced susceptibility to the NRTI combination 
[9]. Despite the degree of baseline resistance, among our survivors, there was a high rate of 
virological suppression and immunological recovery, comparable to findings in other studies 
in both resource-rich and resource-poor settings [20,24]. While our study was not powered 
to detect differences in suppression rates according to varying degrees of resistance, we 
found the presence of more complex resistance genotypes was actually associated with more 
successful suppression on univariate analysis. The presence of the wild type or only low 
genetic barrier resistance mutations (M184V or NNRTI mutations) may suggest recent 
nonadherence as the aetiology of failure for both first- and second-line regimens, whereas 
more highly adherent patients, paradoxically, may have accumulated more mutations in 
response to their failing first-line combination. Alternatively, if patients were recently 
nonadherent, we may have failed to detect minority variants that would suggest high 
resistance. LPV/r has been shown to be an effective monotherapy regimen in ART-naïve 
patients in both the short and longer term [11,12]. The successful suppression of HIV-1 RNA 
in the setting of known extensive genotypic NRTI resistance suggests potential for its use as 
monotherapy after first failure of an NNRTI-based regimen also. Alternatively, residual 
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NRTI activity may be underestimated by genotype and phenotype testing [5,6,8,25]. Longer 
term follow-up will be required to determine the durability of our findings.
Drug toxicity and drug substitutions were common in our study, underscoring the need for 
laboratory capacity in settings where second-line treatment is available. In particular, renal 
toxicity to TDF was somewhat higher than reported in series of first-line treatment of similar 
treatment duration [26,27]. LPV/r has recently been shown to increase TDF concentrations 
[28] and this may explain our findings, although this hypothesis is controversial [29,30]. 
Additionally, ZDV-induced anaemia required frequent substitutions. While genotypic and 
phenotypic resistance results theoretically supported the use of ZDV/3TC/TDF in second-
line treatment [9], the high rates of HIV-1 RNA suppression in patients with the most 
extensive NRTI resistance suggest that the NRTI backbone may unnecessarily complicate 
patient management by frequently inducing toxicity rather than improve virological outcome 
when used in all patients in the absence of prospective resistance testing. Using three NRTIs 
in all patients also increases overall costs. Further studies to determine optimal second-line 
regimens for resource-limited settings are urgently needed.
TB was common in our study population. Malawi follows WHO guidelines for the treatment 
of TB with a 6-month rifampicin-containing regimen, which results in a delay or interruption 
of LPV/r-based second-line ART until completion of the TB treatment, with the associated 
risks of severe morbidity and mortality. Strategies to overcome the unfavourable 
pharmacokinetics have not been successful [31–33], or have led to potentially dangerous 
hepatotoxicity [34]. Rifabutin-based TB treatment, compatible with protease inhibitor 
therapy, has limited availability and experience in its use in resource-limited settings is 
small. We observed successful treatment in all patients we treated with the rifabutin-based 
combination. The addition of rifabutin to the WHO essential drugs list should improve 
availability [35] and allow more successful treatment of both HIV and TB in patients on 
second-line ART.
Given the monitoring strategy used in Malawi, we can assume that a large number of 
virological failure cases were not identified. Within the national programme, as of December 
2008, only 518 (0.3%) of the 145 479 patients known to be alive and on ART had been 
switched to a second-line regimen [3], underscoring the low identification of virological 
failure nationally. We enrolled all consecutive patients beginning second-line treatment at 
both clinics and thus our findings are representative of the treatment outcomes that would be 
expected in an ART programme following a public health approach. Our study is among the 
first descriptions of virological outcomes of second-line treatment in resource-limited 
settings linked to baseline resistance data. While our suppression rates are promising, longer 
duration of follow-up is required.
Our data add to the ongoing debate regarding the optimal way to identify and manage ART 
failure in resource-limited settings. Increasing evidence demonstrates the poor predictive 
value of clinical and immunological definitions of ART failure and the need for viral load 
testing to accurately identify failure [36–38]. Moreover, accumulation of resistance 
mutations with its potentially compromised treatment responses and risk of transmission of 
resistant virus have also prompted calls for earlier failure detection potentially through 
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HIV-1 RNA monitoring [9,10]. Computer modelling of ART outcomes in the setting of 
limited treatment options suggests that virological monitoring will have minimal impact on 
long-term survival [39]. Yet, in a recent home-based care clinical trial in rural Uganda, 
clinical monitoring was associated with an increased risk of death or AIDS-defining event at 
3 years [40]. Additionally, the Development of Antiretroviral Therapy in Africa (DART) 
study confirmed that clinical monitoring alone was associated with a small but significant 
increase in the risk of death and AIDS progression compared with quarterly CD4 cell count 
monitoring [41] but cost effective analysis suggested quarterly CD4 monitoring was not cost 
effective at current prices [42].
Somewhat surprisingly, we demonstrated that extensive NRTI resistance did not adversely 
affect second-line virological and immunological outcomes over a year of follow-up. 
However, we observed substantial, primarily early, mortality and a large proportion of 
survivors experienced new or recurrent WHO stage 3 or 4 illnesses. Our observations argue 
strongly for earlier detection of ART failure, either by a more sensitive clinical/
immunological algorithm or by point-of-care HIV-1 viral load monitoring. Resistance 
testing, while potentially useful, is still very expensive and may be less important for the 
individual patient. The poor response rate in those individuals with the most limited 
resistance and the association of virological failure with nonadherence remind us of the 
importance of adherence in all settings in which ART is administered.
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Patient recruitment and flow chart. ART, antiretroviral therapy; QECH, Queen Elizabeth 
Central Hospital; HIV, human immunodeficiency virus; RNA, ribonucleic acid.
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Kaplan–Meier estimates of proportion of patients with virologically confirmed failure (n = 
106) who were alive after 12 months post identification of failure.
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Trends in HIV-1 RNA suppression (<400 copies/mL) and median CD4 cell counts after 
initiation of second-line antiretroviral therapy to month 12. The lighter line represents the 
intent-to-treat analysis (death/lost = failure) and the darker line represents the as-treated 
analysis (death/lost = excluded). Solid bars represent median CD4 cell counts (death/lost = 
excluded).
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Table 1
Demographics and clinical characteristics of patients at confirmed virological failure (n = 109) and on 
initiation of second-line antiretroviral therapy (ART) (n = 101)
Median (IQR) or %
At virological failure (n = 109) On initiation of second-line ART (n = 101)
Age (years) 37.5 (31.5–46.0) 38.0 (32.0–46.0)
Per cent female 54% 55%
Per cent male 46% 46%
Time on first-line line ART (months) 34.2 (24.5–48.0) 35.2 (25.4–49.0)
 CD4<50 cells/μL 44% 46%
 50 ≤ CD4 ≤ 200 cells/μL 34% 34%
 CD4>200 cells/μL 22% 21%
Body mass index 21.0 (18.4–23.5) 21.2 (18.5–23.6)
Haemoglobin (g/dL) 12.4 (10.7–13.9) 12.3 (10.6–13.9)
Clinical failure 6% 8%
Immunological failure 76% 73%
Both clinical and immunological failure 19% 18%
Active tuberculosis 16% 14%
Kaposi sarcoma 11% 11%
Resistance profile (%)*
 Wild type (no mutations) 5%
 NNRTI ± M184V mutations only 17%
 Any TAMs 56%
 ≥ 3 TAMs 25%
 K65R or K70E 24%
 K65R/70E 1Q151M or 69 insertion 17%
*Resistance testing was only performed on patients initiating second-line ART with a sufficient sample (n = 96, with two nonamplified samples). 
Detailed resistance data are available [9].
IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; TAMs, thymidine analog mutations.
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Table 2
Multivariate analysis evaluating factors associated with death at 6 and 12 months, and death or morbidity at 6 
and 12 months, for all patients identified as having confirmed virological failure (n = 106)
Baseline factor Death by 6 or 12
* months 
adjusted OR (95% CI)
Death or morbidity by 6 
months adjusted OR (95% 
CI)
Death or morbidity by 12 
months adjusted OR (95% 
CI)
Clinical failure 3.47 (1.14–10.59) 2.76 (0.85–8.95) 1.51 (0.49–4.67)
CD4<50 cells/μL 1.09 (0.37–3.27) 3.13 (1.05–9.31) 2.57 (1.01–6.52)
HIV RNA>100 000 copies/mL 1.10 (0.35–3.50) 0.78 (0.24, 2.59) 1.34 (0.49–3.67)
Body mass index <18.5 m2/kg 4.43 (1.15–17.12) 1.99 (0.67–5.86) 1.82 (0.66–5.00)
Haemoglobin <10 g/dL 2.97 (0.87–10.08) 3.60 (0.97–13.3) 1.82 (.056, 5.91)
Duration of ART>3 years prior to 
identified failure
1.74 (0.37, 8.24) 2.10 (0.69–6.36) 0.46 (0.20, 1.03)
Values in bold denote statistical significance.
*No deaths occurred after 6 months therefore analysis at 6 and 12 months is identical.
ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio; HIV, human immunodeficiency virus; RNA, ribonucleic acid.
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Table 3
Univariate and multivariate analysis evaluating factors associated with failure to achieve HIV RNA<400 
copies/mL at 12 months in patients initiating second-line antiretroviral therapy (ART) (n = 101)
Predictor OR (95% CI) aOR (95% CI)
Age <18 years 3.96 (0.67, 13.0) 1.63 (0.15, 17.2)
Female gender 2.00 (0.57, 7.00) 5.92 (0.95, 36.76)
ART>3 years 0.31 (0.08, 1.20) 0.50 (0.10, 2.42)
 CD4<50 cells/μL 8.6 (2.40, 30.78) 1.34 (0.17, 10.81)
 50 ≤ CD4 ≤ 200 cells/μL 2.10 (0.67, 6.49) 1.06 (0.14, 8.19)
 CD4>200 cells/μL 1.0 1.0
HIV RNA>100 000 copies/mL 3.47 (1.08, 11.09) 0.79 (0.15, 4.19)
WHO clinical failure 11.54 (1.48, 90.21) 1.33 (0.24, 7.44)
WHO immunological failure 54.21 (14.5, 202.7)
Resistance profile
 ≥ 2 active NRTIs (‘low’) 1.0
 1 active NRTI (‘medium’) 0.45 (0.16, 1.2)
 No active NRTIs (‘high’) 0.17 (0.03, 0.94)
Ever missed a dose/not 3.15 (0.90, 11.05) 5.70 (1.16, 27.93)
Number of missed visits 2.50 (1.35, 4.63)
Haemoglobin <10 g/dL 0.82 (0.16, 4.11) 1.15 (0.17, 7.87)
Body mass index <18.5 2.75 (0.85, 8.85) 2.09 (0.33, 13.30)
Tuberculosis diagnosis (baseline or during study) 1.09 (0.21, 5.54) 0.86 (0.08, 9.36)
Values in bold denote statistical significance.
WHO immunological failure dropped for the multivariate analysis because of collinearity with CD4 cell count categories; the number of missed 
visits decreased for the multivariate analysis because of collinearity with ever missed a dose/not. The resistance profile decreased in the multivariate 
analysis because of missing values (n = 7).
aOR, adjusted odds ratio; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; WHO, World Health Organization.
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